Table 4.
Relationship between immunochemical features and tumor stage.
| Target Expression | Ta | Tis | T1 | T2 | ≥T3, N+ or M+ | p-Value |
|---|---|---|---|---|---|---|
| VEGFA | ||||||
| 1 | 7 (17.5%) | 4 (23.5%) | 11 (20.4%) | 8 (33.3%) | 5 (17.9%) | 0.854 |
| 2 | 10 (25.0%) | 6 (35.3%) | 12 (22.2%) | 7 (29.2%) | 7 (25.0%) | |
| 3 | 11 (27.5%) | 4 (23.5%) | 17 (31.5%) | 3 (12.5%) | 10 (35.7%) | |
| 4 | 12 (30.0%) | 3 (17.6%) | 14 (25.9%) | 6 (25.0%) | 6 (21.4%) | |
| MMP9 | ||||||
| 1 | 5 (11.6%) | 1 (7.1%) | 5 (8.9%) | 7 (24.1%) | 3 (8.6%) | 0.1389 |
| 2 | 6 (14.0%) | 7 (50.0%) | 16 (28.6%) | 3 (10.3%) | 7 (20.0%) | |
| 3 | 17 (39.5%) | 3 (21.4%) | 16 (28.6%) | 7 (24.1%) | 13 (37.1%) | |
| 4 | 15 (34.9%) | 3 (21.4%) | 19 (33.9%) | 12 (41.4%) | 12 (34.3%) | |
| MMP10 | ||||||
| 1 | 14 (32.6%) | 5 (35.7%) | 12 (21.8%) | 3 (10.3%) | 1 (2.8%) | 0.0103 |
| 2 | 3 (7.0%) | 4 (28.6%) | 9 (16.4%) | 6 (20.7%) | 7 (19.4%) | |
| 3 | 15 (34.9%) | 4 (28.6%) | 17 (30.9%) | 5 (17.2%) | 12 (33.3%) | |
| 4 | 11 (25.6%) | 1 (7.1%) | 17 (30.9%) | 15 (51.7%) | 16 (44.4%) | |
| PAI1 | ||||||
| 1 | 6 (14.3%) | 2 (13.3%) | 1 (1.8%) | 2 (7.1%) | 0 (0%) | 0.013 |
| 2 | 11 (26.2%) | 8 (53.3%) | 18 (32.1%) | 6 (21.4%) | 8 (22.9%) | |
| 3 | 13 (31.0%) | 5 (33.3%) | 14 (25.0%) | 8 (28.6%) | 17 (48.6%) | |
| 4 | 12 (28.6%) | 0 (0%) | 23 (41.1%) | 12 (42.9%) | 10 (28.6%) | |
| IL8 | ||||||
| 1 | 18 (39.1%) | 7 (43.8%) | 17 (28.3%) | 5 (17.2%) | 13 (35.1%) | 0.7881 |
| 2 | 8 (17.4%) | 3 (18.8%) | 17 (28.3%) | 8 (27.6%) | 9 (24.3%) | |
| 3 | 9 (19.6%) | 4 (25.0%) | 12 (20.0%) | 6 (20.7%) | 7 (18.9%) | |
| 4 | 11 (23.9%) | 2 (12.5%) | 14 (23.3%) | 10 (34.5%) | 8 (21.6%) | |
| CA9 | ||||||
| 1 | 3 (6.7%) | 0 (0%) | 6 (10.0%) | 8 (27.6%) | 6 (15.8%) | 0.0192 |
| 2 | 16 (35.6%) | 5 (29.4%) | 9 (15.0%) | 3 (10.3%) | 12 (31.6%) | |
| 3 | 13 (28.9%) | 7 (41.2%) | 18 (30.0%) | 7 (24.1%) | 13 (34.2%) | |
| 4 | 13 (28.9%) | 5 (29.4%) | 27 (45.0%) | 11 (37.9%) | 7 (18.4%) | |
| APOE | ||||||
| 1 | 9 (19.1%) | 2 (12.5%) | 14 (23.7%) | 6 (20.7%) | 5 (13.9%) | 0.967 |
| 2 | 12 (25.5%) | 3 (18.8%) | 10 (16.9%) | 8 (27.6%) | 8 (22.2%) | |
| 3 | 14 (29.8%) | 6 (37.5%) | 15 (25.4%) | 7 (24.1%) | 11 (30.6%) | |
| 4 | 12 (25.5%) | 5 (31.3%) | 20 (33.9%) | 8 (27.6%) | 12 (33.3%) | |
| A1AT | ||||||
| 1 | 16 (36.4%) | 4 (26.7%) | 22 (37.9%) | 6 (21.4%) | 10 (29.4%) | 0.403 |
| 2 | 18 (40.9%) | 4 (26.7%) | 15 (25.9%) | 8 (28.6%) | 8 (23.5%) | |
| 3 | 7 (15.9%) | 4 (26.7%) | 15 (25.9%) | 7 (25.0%) | 8 (23.5%) | |
| 4 | 3 (6.8%) | 3 (20.0%) | 6 (10.3%) | 7 (25.0%) | 8 (23.5%) | |
| SDC1 | ||||||
| 1 | 3 (7.1%) | 7 (36.8%) | 2 (3.4%) | 5 (17.2%) | 5 (14.3%) | <0.0001 |
| 2 | 5 (11.9%) | 5 (26.3%) | 10 (16.9%) | 7 (24.1%) | 16 (45.7%) | |
| 3 | 10 (23.8%) | 2 (10.5%) | 24 (40.7%) | 11 (37.9%) | 10 (28.6%) | |
| 4 | 24 (57.1%) | 5 (26.3%) | 23 (39.0%) | 6 (20.7%) | 4 (11.4%) | |
| ANG | ||||||
| 1 | 2 (4.3%) | 0 (0%) | 0 (0%) | 3 (10.3%) | 0 (0%) | 0.003 |
| 2 | 17 (37.0%) | 11 (64.7%) | 14 (23.7%) | 4 (13.8%) | 8 (22.2%) | |
| 3 | 13 (28.3%) | 1 (5.9%) | 22 (37.3%) | 10 (34.5%) | 17 (47.2%) | |
| 4 | 14 (30.4%) | 5 (29.4%) | 23 (39.0%) | 12 (41.4%) | 11 (30.6%) | |
| CD3+ | ||||||
| 1 | 12 (31.6%) | 1 (12.5%) | 14 (29.2%) | 1 (4.8%) | 10 (29.4%) | 0.444 |
| 2 | 8 (21.1%) | 1 (12.5%) | 10 (20.8%) | 8 (38.1%) | 10 (29.4%) | |
| 3 | 7 (18.4%) | 3 (37.5%) | 13 (27.1%) | 5 (23.8%) | 9 (26.5%) | |
| 4 | 11 (28.9%) | 3 (37.5%) | 11 (22.9%) | 7 (33.3%) | 5 (14.7%) | |
| CD68+ | ||||||
| 1 | 17 (42.5%) | 5 (55.6%) | 9 (18.0%) | 2 (8.7%) | 6 (17.7%) | 0.010 |
| 2 | 11 (27.5%) | 1 (11.1%) | 15 (30.0%) | 5 (21.7%) | 7 (20.6%) | |
| 3 | 9 (22.5%) | 3 (33.3%) | 13 (26.0%) | 7 (30.4%) | 8 (23.5%) | |
| 4 | 3 (7.5%) | 0 (0.0%) | 13 (26.0%) | 9 (39.1%) | 13 (38.2%) |
Bolded denotes significance.